ANAB AnaptysBio Corp: Earnings per share for the last twelve months
AnaptysBio, Inc. (ANAB) focuses on developing antibodies to combat inflammation, monetizing its research through licensing agreements and molecule outsourcing. The TTM revenue per share reflects the trend in unit profit, where the metric stands at 6.43. The company ensures the sustainability of its research through royalties, integrating strict environmental standards and bioethics into the production of immunological drugs.
Analytical breakdowns and data insights for company AnaptysBio Inc (ANAB)
- current quotes and average value forecast:
- company stock capitalization data:
- shareholders' equity book value data:
- debt and liquidity data:
Total Debt to Capital AnaptysBio, Inc.|ANAB - Long-Term Liabilities to Capital|Short-Term Debt to Capital AnaptysBio Corp|ANAB - Company Aggregate Debts|Debt to Book Capitalization Ratio AnaptysBio, Inc.|ANAB - Company Long-Term Indebtedness|Company Short-Term Debts AnaptysBio|Quick Liquidity anaptysbio.com
- earnings and valuation multiples indicators:
ANAB - Profit After Tax|Future Profit AnaptysBio, Inc.|ANAB - Market Price to Net Income Ratio|Projected Price to Earnings AnaptysBio|ANAB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AnaptysBio, Inc.|ANAB - Operating income before deduction of amortization|Net earnings per share (EPS TTM) AnaptysBio|ANAB - Earnings per share for the last twelve months|Quarterly EPS earnings growth anaptysbio.com|ANAB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year AnaptysBio, Inc.
Analysis of all company metrics:ANAB - AnaptysBio, Inc.
Net income per share over 12 months measures the portion of total income attributable to a single security, allowing for an assessment of the actual efficiency of the business capitalization. The 12-month net income per share trend for AnaptysBio, Inc. (ANAB) reflects the stability of antibody licensing revenues, confirming the resilience of cash flows and the reliability of the company's investment profile.
Direct competitors
ARGX - Earnings per share for the last twelve months|biontech.de (BNTX) - Net earnings per share for the last 12 months|Abivax Pharma (ABVX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months ADMA Biologics Inc|Net earnings per share for the last 12 months PTGX|Net earnings per share (EPS TTM) Immunovant Therapeutics|Earnings per share for the last twelve months Kiniksa Pharmaceuticals (KNSA)|grifols.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) ADPT (Adaptive Biotechnologies Corporation)|Celldex Therapeutics Inc (CLDX) - Net earnings per one share for the last twelve months|Aurinia Pharma - Net earnings per share (EPS TTM)|BCRX - Net earnings per share (EPS TTM)|Vera Therapeutics, Inc. (VERA) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DNTH|PHVS (Pharvaris) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) AbCellera Biologics Inc|Earnings per share for the last twelve months Tourmaline Corp (TRML)|PGEN: Earnings per one share for the last 12 months|Pharming Group N.V. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters NKTR (nektar.com)|UPB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Zenas Bio|Immunome Corp (IMNM) - Earnings per share for the last twelve months|GOSS - Net earnings per share for the last four quarters|KALV (KalVista Pharmaceuticals) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SEPN|Net earnings per share (EPS TTM) PVLA|Net earnings per share for the last four quarters Savara Inc|Earnings per share for the last twelve months Rigel Pharmaceuticals Inc RIGL|Astria Corp (ATXS) - Net earnings per one share for the last twelve months|ENGN: Net earnings per share for the last 12 months|Earnings per share for the trailing year RAPT (RAPT Therapeutics Inc.)|JBIO: Net earnings per share (EPS TTM)|ACRS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Kyverna|Earnings per share for the last 12 months TLSA (Tiziana Life Sciences, Ltd.)|Net earnings per share (EPS TTM) CABA|Net earnings per share for the last 12 months ventyxbio.com VTYX|Theratechnologies - Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Avalo Therapeutics, Inc. (AVTX)|Eledon - Net earnings per share (EPS TTM)|AGEN - Net earnings per share (EPS TTM)|Climb Bio Inc (CLYM) - Earnings per share for the last twelve months|Earnings per share for the last 12 months ZURA|ATYR (aTyr Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Adagene Corp|Net earnings per share (EPS TTM) IMA|Earnings per share for the last twelve months STTK (shattucklabs.com)|Earnings per share for the last twelve months Equillium EQ|CNTB (Connect Biopharma Holdings) - Earnings per one share for the last 12 months|Immunic Inc - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ATRA (Atara Biotherapeutics)|IFRX: Net earnings per share (EPS TTM)|X4 Pharmaceuticals, Inc (XFOR) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Adicet Bio Inc.|CELU: Earnings per share for the trailing year|Earnings per share for the last twelve months INmune Bio (INMB)|Net earnings per share for the last 12 months Barinthus Biotherapeutics PLC BRNS|Net earnings per share (EPS TTM) KZR (Kezar Life Sciences, Inc)|Net earnings per share (EPS TTM) SAB Biotherapeutics Inc SABS|AKTX: Net earnings per share for the last 12 months|Earnings per share for the trailing year ENLV (Enlivex Therapeutics)|QTTB: Net earnings per share (EPS TTM)|GOVX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Edesa|Net earnings per share for the last 12 months iBio Corporation (IBIO)|Earnings per share for the last twelve months Carisma Therapeutics (CARM)|Net earnings per share for the last 12 months xtlbio.com XTLB|Bolt Biotherapeutics, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) HCW Biologics, Inc. HCWB|APVO - Earnings per share for the last twelve months|AIM (AIM ImmunoTech, Inc.) - Earnings per share for the last 12 months|ADTX: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months gribio.com (GRI)|XRTX (XORTX Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Vyome Holdings Inc.|Earnings per share for the last twelve months Revelation Bio (REVB)|Indaptus Corp - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) SCNI (Scinai Immunotherapeutics)|Net earnings per share (EPS TTM) CalciMedica Inc CALI|AFMD - Earnings per share for the last twelve months|Earnings per one share for the last 12 months ALLK|HOOK (hookipapharma.com) - Net earnings per share for the last 12 months|IGMS: Earnings per share for the last four quarters|Net earnings per share for the last 12 months ITOS|Net earnings per one share for the last twelve months oceanbiomedical.com OCEA|Earnings per share for the last twelve months TC BioPharm (TCBP)|Net earnings per share for the last four quarters Third Harmonic Bio Inc.
